Pharming Group's Strong Performance and Growth Prospects Justify Buy Rating
Pharming Analyst Ratings
Pharming Group's Strong Financial Performance and Growth Potential Merit Buy Rating
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG) and Pharming Group (OtherPHGUF)
Pharming Group: Strong Buy Rating on Robust Revenue Growth and Promising Clinical Pipeline Expansion
Pharming Group's Promising Clinical Trials and Regulatory Advancements Drive Analyst's Buy Rating
Pharming Group (PHGUF) Receives a Buy From RBC Capital
Pharming Group (PHAR) Gets a Buy From Oppenheimer
Analysts Offer Insights on Healthcare Companies: Ambrx Biopharma (AMAM), Santhera Pharmaceuticals Holding (OtherSPHDF) and Pharming Group (OtherPHGUF)
Pharming Group's Stock Positioned for Growth: Strong Performance of Ruconest and Promising Launch of Joenja Bolster Buy Rating
RBC Capital Reaffirms Their Buy Rating on Pharming Group (PHGUF)
H.C. Wainwright Keeps Their Buy Rating on Pharming Group (PHAR)
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
Pharming Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Pharming Group (PHAR), SurModics (SRDX) and REPRO-MED Systems (KRMD)
RBC Capital Sticks to Their Buy Rating for Pharming Group (PHGUF)
H.C. Wainwright Remains a Buy on Pharming Group (PHAR)
Oppenheimer Maintains Outperform on Pharming, Raises Price Target to $40
Oppenheimer Adjusts Pharming Group Price Target to $40 From $36, Maintains Outperform Rating
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
No Data